GLP-1 'month update' videos: what the science says vs. the hype
Quick answer
The creator is one month into liraglutide 3.0 mg (Saxenda) for weight management, reporting significant early weight loss alongside GI side effects including nausea, vomiting, and constipation consistent with the drug's known adverse effect profile. Her self-reported 26.8-pound loss in 30 days exceeds average trial outcomes and likely includes fluid and glycogen-related weight, not solely adipose tissue. Patients vomiting frequently on liraglutide should discuss electrolyte monitoring and possible dose adjustment with their prescribing clinician rather than managing symptoms with hydration alone.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @shanna_beth actually say?
She started liraglutide (Saxenda) one month ago, lost 26.8 pounds in that first month, and is now doing her second injection. She described early nausea as "horrible," said constipation is ongoing, and shared that overeating on liraglutide, even one dinner roll, made her too full to finish a meal. She credited her boyfriend's support as essential to sticking with treatment.
She didn't claim liraglutide cures anything, didn't cite doses, and didn't make outlandish health claims. The video is a personal progress update, not a medical tutorial. That framing matters when evaluating what she got right and wrong.
Does the science back this up?
Partially. The side effects she described, nausea, vomiting, and constipation, are well-documented. The weight loss number, however, is unusually high for one month on liraglutide specifically and deserves scrutiny.
The SCALE Obesity trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that liraglutide 3.0 mg produced an average weight loss of about 8% of body weight over 56 weeks in people without diabetes. That's a slow, cumulative result. Losing 26.8 pounds in a single month would require an extraordinary caloric deficit, especially given that she described barely eating due to nausea and vomiting. It's plausible that a significant portion of that early loss is water weight, glycogen depletion, or loss of stool weight from reduced food intake, not fat mass. Early rapid losses on GLP-1 medications are documented, but 26 pounds in 30 days on liraglutide specifically is at the high end of what the literature would predict.
Her observation about early nausea improving over time also matches the data. Mehta et al. (2017, Obesity Reviews) confirmed that GI side effects on liraglutide peak early and tend to subside with dose titration.
What did they get right or wrong?
She got the side effect profile right. Nausea, vomiting, and constipation are the three most commonly reported adverse effects of liraglutide in clinical trials, and her description of them tracks with what patients actually experience.
She also correctly identified overeating as a risk. GLP-1 receptor agonists delay gastric emptying and suppress appetite, which means overeating doesn't just cause discomfort, it can trigger significant nausea and vomiting. Her Texas Roadhouse story is a real-world illustration of what clinicians call "portion dysregulation" during early treatment.
What she got wrong, or at least incomplete, is the nutrient loss framing. She said she felt she "lost a lot of nutrients" from vomiting. This isn't technically inaccurate as a concern, but it's vague enough to be misleading. Prolonged vomiting on GLP-1 drugs can contribute to electrolyte imbalances, particularly low potassium and magnesium. Simply "drinking water" and staying "caught up with nutrients" is a reasonable instinct but doesn't address the specific deficiencies worth monitoring. Patients on these medications who vomit frequently should be talking to their prescribers about lab monitoring, not just hydrating more.
The 26.8-pound claim is almost certainly real to her scale, but presenting it as a clean "26 pounds of fat gone" is misleading by omission.
What should you actually know?
Liraglutide (Saxenda) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. It works differently from semaglutide and tirzepatide in both mechanism and magnitude of effect. Average weight loss in trials is more modest than what many influencers report.
Early dramatic weight loss on any GLP-1 medication often includes fluid shifts and reduced gut contents, not just fat loss. This doesn't mean it isn't working. It means the number on the scale in week four is not the number that reflects your long-term trajectory.
If you're experiencing frequent vomiting on liraglutide, contact your prescriber. It may indicate you're titrating too fast, or it may warrant a temporary dose hold. Managing these side effects proactively affects both your quality of life and your ability to stay on treatment long enough to see real metabolic results.
Her point about support systems is genuinely underrated in clinical conversations. Adherence data on GLP-1 medications is sobering. A 2023 analysis by Wharton et al. in Obesity found that a significant percentage of patients discontinue within the first year. Social support is one of the factors associated with better retention.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 'month update' videos: what the science says vs. the hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 'month update' videos: what the science says vs. the hype is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is one month into liraglutide 3.
FormBlends verdict
The creator is one month into liraglutide 3.0 mg (Saxenda) for weight management, reporting significant early weight loss alongside GI side effects including nausea, vomiting, and constipation consistent with the drug's known adverse effect profile. Her self-reported 26.8-pound loss in 30 days exceeds average trial outcomes and likely includes fluid and glycogen-related weight, not solely adipose tissue. Patients vomiting frequently on liraglutide should discuss electrolyte monitoring and possible dose adjustment with their prescribing clinician rather than managing symptoms with hydration alone.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is one month into liraglutide 3.0 mg (Saxenda) for weight management, reporting significant early weight loss alongside GI side effects including nausea, vomiting, and constipation consistent with the drug's known adverse effect profile. Her self-reported 26.8-pound loss in 30 days exceeds average trial outcomes and likely includes fluid and glycogen-related weight, not solely adipose tissue. Patients vomiting frequently on liraglutide should discuss electrolyte monitoring and possible dose adjustment with their prescribing clinician rather than managing symptoms with hydration alone.
- The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) showed average liraglutide weight loss of about 8% of body weight over 56 weeks, so 26.8 pounds in one month likely includes fluid and glycogen weight, not just fat.
- Nausea and vomiting on liraglutide are most severe during early dose titration and typically improve, which matches what the creator described and what clinical data supports.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) showed average liraglutide weight loss of about 8% of body weight over 56 weeks, so 26.8 pounds in one month likely includes fluid and glycogen weight, not just fat.
- Nausea and vomiting on liraglutide are most severe during early dose titration and typically improve, which matches what the creator described and what clinical data supports.
- Constipation affects roughly 19% of liraglutide users in trials and is caused by the drug slowing gastric emptying, not dietary factors alone.
- Patients vomiting frequently on GLP-1 medications should ask their prescriber about electrolyte lab monitoring, as potassium and magnesium depletion are real risks beyond general dehydration.
- Real-world discontinuation rates for GLP-1 weight loss medications are significant within the first year, and behavioral support systems are associated with better treatment retention per Wharton et al. (2023, Obesity).
- Overeating on liraglutide carries a higher-than-normal risk of nausea and vomiting because the drug delays gastric emptying, meaning stomach capacity is functionally reduced.
- Liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) are distinct drugs with different mechanisms and average efficacy profiles and should not be assumed to produce identical results.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Shanna_Beth · TikTok creator
208.6K views on this video
Wooo what a month it has been!!
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Shanna_Beth, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.